Despite early data identifying expression of PD-L1 on tumor cells as being associated with response to anti-PD-1/PD-L1 monotherapy, that characteristic alone is not currently suitable for clinical decision-making in patients with melanoma. The gene discussed is PDCD1; the disease is neoplasm.